纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | BTN2A2 |
Uniprot No | Q8WVV5 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 33-262aa |
氨基酸序列 | QFTVVGPANPILAMVGENTTLRCHLSPEKNAEDMEVRWFRSQFSPAVFVYKGGRERTEEQMEEYRGRITFVSKDINRGSVALVIHNVTAQENGIYRCYFQEGRSYDEAILRLVVAGLGSKPLIEIKAQEDGSIWLECISGGWYPEPLTVWRDPYGEVVPALKEVSIADADGLFMVTTAVIIRDKYVRNVSCSVNNTLLGQEKETVIFIPESFMPSASPWMVALAVILTAS |
预测分子量 | 41.7 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BTN2A2重组蛋白的模拟参考文献示例(实际文献需通过数据库验证):
1. **文献名称**: "BTN2A2 modulates γδ T cell-mediated antitumor immunity through regulation of lipid metabolism"
**作者**: Smith A, et al.
**摘要**: 研究通过重组BTN2A2蛋白实验,揭示其通过与γδ T细胞表面受体互作,调控脂质代谢相关信号通路,增强肿瘤微环境中T细胞的抗肿瘤活性。
2. **文献名称**: "Structural characterization of recombinant BTN2A2 and its interaction with BTN3A1 in antigen presentation"
**作者**: Chen L, et al.
**摘要**: 利用重组BTN2A2蛋白进行晶体结构解析,发现其与BTN3A1形成复合物,参与抗原呈递过程,为自身免疫疾病治疗提供潜在靶点。
3. **文献名称**: "Recombinant BTN2A2 as a biomarker in colorectal cancer: Expression analysis and clinical correlation"
**作者**: Wang Y, et al.
**摘要**: 通过重组蛋白技术检测BTN2A2在结直肠癌患者组织中的表达水平,发现其高表达与免疫细胞浸润增加及患者生存期延长显著相关。
4. **文献名称**: "BTN2A2 recombinant protein inhibits viral entry by blocking envelope protein-host membrane fusion"
**作者**: Kumar R, et al.
**摘要**: 体外实验表明,重组BTN2A2蛋白通过竞争性结合病毒囊膜蛋白,抑制HIV-1等病毒的宿主细胞膜融合过程,提示其抗病毒治疗潜力。
注:以上内容为模拟简化摘要,实际文献需查阅PubMed/Google Scholar等平台。
Butyrophilin subfamily 2 member A2 (BTN2A2) is a transmembrane glycoprotein belonging to the butyrophilin (BTN) family, which shares structural homology with the B7 family of immune regulators. Primarily expressed in immune cells and certain epithelial tissues, BTN2A2 is implicated in modulating both innate and adaptive immune responses. Structurally, it contains immunoglobulin (Ig)-like V and C1 domains in its extracellular region, a feature common to proteins involved in cell-cell interactions and immune signaling. Unlike other BTN members like BTN3A1 (linked to γδ T cell activation via phosphoantigens), BTN2A2’s exact mechanistic role remains less defined but is thought to involve interactions with γδ T cells, dendritic cells, or other immune checkpoints.
Recent studies suggest BTN2A2 may regulate T-cell receptor (TCR) signaling, potentially acting as a co-stimulatory or co-inhibitory molecule depending on context. It has also been associated with lipid antigen presentation, though its ligands remain uncharacterized. In cancer biology, BTN2A2 is explored as a biomarker or therapeutic target due to its altered expression in tumors and potential role in immune evasion. Additionally, BTN2A2 interacts with BTN3A1. hinting at collaborative functions in immune surveillance.
Recombinant BTN2A2 protein, typically produced in mammalian systems (e.g., HEK293 cells) to ensure proper glycosylation, is widely used in vitro to study ligand-receptor interactions, immune cell activation/inhibition, and downstream signaling pathways. Its applications extend to antibody development, structural studies, and screening for immunotherapies targeting BTN-related pathways. Despite progress, further research is needed to clarify its physiological ligands, signaling cascades, and therapeutic potential in autoimmune diseases, infections, and oncology.
×